Kohei Fujita1, Naohiro Uchida2, Osamu Kanai2, Misato Okamura2, Koichi Nakatani2, Tadashi Mio2. 1. Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, 1-1, Fukakusa-Mukaihata-Cho, Fushimi-Ku, Kyoto, Japan. kfujita-oka@umin.ac.jp. 2. Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, 1-1, Fukakusa-Mukaihata-Cho, Fushimi-Ku, Kyoto, Japan.
Abstract
PURPOSE: After approval of anti-programmed cell death (PD)-1 antibodies, treatment for non-small cell lung cancer (NSCLC) has drastically changed. However, even in patients with favorable effects, therapeutic efficacy does not last long. Recently, retreatment with anti-PD-1 antibody has received attention. The aim of this study was to evaluate the efficacy and safety of retreatment with pembrolizumab in NSCLC patients previously treated with nivolumab. PATIENTS AND METHODS: We retrospectively reviewed NSCLC patients retreated with pembrolizumab who were previously treated with nivolumab. We collected the following data: patient characteristics, number of cycles of nivolumab and pembrolizumab, treatment interval between nivolumab and pembrolizumab, best response, and immune-related adverse events. RESULTS: Twelve patients were reviewed. The median number of cycles of nivolumab was 12.5 (range 2-32 cycles). Seven patients (58.3%) achieved a partial response (PR) and two patients (16.7%) achieved stable disease (SD). Eight patients (66.7%) received cytotoxic chemotherapy between nivolumab and pembrolizumab. The median number of cycles of chemotherapy treatment was 4 (range 1-9 cycles). The median number of cycles of pembrolizumab was 3.5 (range 1-17 cycles). One patient (8.3%) achieved PR and four patients (33.3%) achieved SD as their best response to pembrolizumab. All patients showing response to pembrolizumab had very high (≥ 80%) tumor PD-Ligand 1 expression. CONCLUSIONS: This study suggested that retreatment with anti-PD-1 antibody is a reasonable option for selected NSCLC patients.
PURPOSE: After approval of anti-programmed cell death (PD)-1 antibodies, treatment for non-small cell lung cancer (NSCLC) has drastically changed. However, even in patients with favorable effects, therapeutic efficacy does not last long. Recently, retreatment with anti-PD-1 antibody has received attention. The aim of this study was to evaluate the efficacy and safety of retreatment with pembrolizumab in NSCLCpatients previously treated with nivolumab. PATIENTS AND METHODS: We retrospectively reviewed NSCLCpatients retreated with pembrolizumab who were previously treated with nivolumab. We collected the following data: patient characteristics, number of cycles of nivolumab and pembrolizumab, treatment interval between nivolumab and pembrolizumab, best response, and immune-related adverse events. RESULTS: Twelve patients were reviewed. The median number of cycles of nivolumab was 12.5 (range 2-32 cycles). Seven patients (58.3%) achieved a partial response (PR) and two patients (16.7%) achieved stable disease (SD). Eight patients (66.7%) received cytotoxic chemotherapy between nivolumab and pembrolizumab. The median number of cycles of chemotherapy treatment was 4 (range 1-9 cycles). The median number of cycles of pembrolizumab was 3.5 (range 1-17 cycles). One patient (8.3%) achieved PR and four patients (33.3%) achieved SD as their best response to pembrolizumab. All patients showing response to pembrolizumab had very high (≥ 80%) tumor PD-Ligand 1 expression. CONCLUSIONS: This study suggested that retreatment with anti-PD-1 antibody is a reasonable option for selected NSCLCpatients.
Authors: Shaan Dudani; Jeffrey Graham; J Connor Wells; Ziad Bakouny; Sumanta K Pal; Nazli Dizman; Frede Donskov; Camillo Porta; Guillermo de Velasco; Aaron Hansen; Marco Iafolla; Benoit Beuselinck; Ulka N Vaishampayan; Lori A Wood; Elizabeth Liow; Flora Yan; Takeshi Yuasa; Georg A Bjarnason; Toni K Choueiri; Daniel Y C Heng Journal: Eur Urol Date: 2019-08-22 Impact factor: 20.096
Authors: Marco Russano; Alessio Cortellini; Raffaele Giusti; Alessandro Russo; Federica Zoratto; Francesca Rastelli; Alain Gelibter; Rita Chiari; Olga Nigro; Michele De Tursi; Sergio Bracarda; Stefania Gori; Francesco Grossi; Melissa Bersanelli; Lorenzo Calvetti; Vincenzo Di Noia; Mario Scartozzi; Massimo Di Maio; Paolo Bossi; Alfredo Falcone; Fabrizio Citarella; Francesco Pantano; Corrado Ficorella; Marco Filetti; Vincenzo Adamo; Enzo Veltri; Federica Pergolesi; Mario Alberto Occhipinti; Linda Nicolardi; Alessandro Tuzi; Pietro Di Marino; Serena Macrini; Alessandro Inno; Michele Ghidini; Sebastiano Buti; Giuseppe Aprile; Eleonora Lai; Marco Audisio; Salvatore Intagliata; Riccardo Marconcini; Davide Brocco; Giampiero Porzio; Marta Piras; Erika Rijavec; Francesca Simionato; Clara Natoli; Marcello Tiseo; Bruno Vincenzi; Giuseppe Tonini; Daniele Santini Journal: Cancer Immunol Immunother Date: 2021-08-31 Impact factor: 6.968
Authors: Michele Maio; Michael Lahn; Anna Maria Di Giacomo; Alessia Covre; Luana Calabrò; Ramy Ibrahim; Bernard Fox Journal: J Exp Clin Cancer Res Date: 2021-07-23